Cholesterol and lipid medicines

Hypolipidaemic agents

This page about cholesterol and lipid medicines automatically lists related information collected from other pages of our website.

The Cholesterol and lipid medicines subcategory of medicines is also known as anticholesteraemic agents, cholesterol lowering medicines, dyslipidaemia, medicines for, lipid-lowering medicines, lipid-modifying medicines and hypolipidaemic agents.

Consumers: If you have any questions about medicines, you can speak to one of our pharmacists at NPS Medicines Line by calling 1300 633 424. You can ring Monday to Friday, 9 am to 5 pm, Australian Eastern Standard Time (excluding NSW public holidays). For non-medicine products, further information may also be available from the manufacturer.

Related information - cholesterol and lipid medicines


(Media release)
01 Aug 2016 The latest issue of Australian Prescriber lists the top 10 drugs used in Australia and shows there is an emerging challenge of funding new and expensive drugs.
31 May 2016 Type 2 diabetes can cause complications that require additional medicines. Read about diabetes-related health problems and drugs used to treat them here.
(Media release)
02 May 2016 Many Australians who are at risk of heart attack or stroke are not receiving recommended medications. Find out more about cardiovascular disease prevention.
For health professionals (Health professional publication)
30 Jan 2015 A trial in patients with acute coronary syndromes reaffirms the safety and efficacy of a lipid-modifying drug (ezetimibe) when added to statin therapy (simvastatin) for treating elevated LDL-C level in high-risk patients.
09 Dec 2014 Recent studies of fish oil supplements have found it's unlikely they help reduce heart attacks or strokes in people who already have cardiovascular problems.
For health professionals (Health professional publication)
31 Jul 2014 Table of advantages and disadvantages of glucose-lowering drugs
For health professionals (CPD activity)
27 May 2014 Address the cardiovascular risk of a 49-year old man who is concerned that he is at high risk of having a heart attack.
(Media release)
12 May 2014 NPS MedicineWise has welcomed the ABC’s ruling — published today — that its Catalyst program aired in October 2013 on statins and heart disease breached its own standards on impartiality.
(Consumer publication)
02 May 2014 Current clinical trial evidence does not support the use of Co-enzyme Q10 supplements to prevent muscle pain (myalgia), which is a known possible side effect of using statins.
(Media release)
14 Feb 2014 NPS MedicineWise is reminding health professionals that while various media reports have recently linked statins to a variety of adverse events and questioned their efficacy, these drugs remain one of the most effective strategies for reducing the risk of cardiovascular disease (CVD).

Active ingredients used in cholesterol and lipid medicines